Altered glycosylation in tumours focused to cancer diagnosis

Disease Markers

Volumn 25, Issue 4-5, 2008, Pages 207-218

  Peracaula, Rosa ^a   Barrabés, Sílvia ^a   Sarrats, Ariadna ^a   Rudd, Pauline M ^b   De Llorens, Rafael ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Glycosylation; Human pancreatic ribonuclease; Prostate specific antigen; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CA 549 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCAN; PANCREATIC RIBONUCLEASE; PLASMA PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; HUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW;

EID: 58149397996     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/797629     Document Type: Review

References (71)

1. L. Spinney, Caught in time, Nature 442 (2006), 736-738.
2. M.J. Hayat, N. Howlader, M.E. Reichman and B.K. Edwards, Cancer Statistics, Trends, and Multiple Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program, Oncologist 12 (2007), 20-37.
3. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J Thun, Cancer Statistics, 2007, CA Cancer J Clin, 57 (2007), 43-66.
4. R. Etzioni, N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. Reid, J. Radich, G. Anderson and L. Hartwell, The Case for Early Detection, Nat Rev Cancer 3 (2003), 1-10.
5. H. Varmus, The New Era in Cancer Research, Science 312 (2006), 1162-1165.
6. R. Molina and X. Filella, Marcadores Tumorales, Estado Actual Y Perspectivas de Futuro II, Ed., Roche Diagnostics SL. Lab Diagnostics, Spain, 2003.
7. W.S. Dalton and S.H. Friend, Cancer Biomarkers - An Invitation to the Table, Science 312 (2006), 1165-1168.
8. P.R. Srinivas, B.S. Kramer and S. Srivastava, Trends in Biomarker Research for Cancer Detection, Lancet Oncol 2 (2001), 698-704.
9. R.S. Negm, M. Verma and S. Srivastava, The Promise of Biomarkers in Cancer Screening and Detection, Trends Mol Med 8 (2002), 288-293.
10. K. Bensalah, F. Montorsi and SF. Shariat, Challenges of Cancer Biomarker Profiling, Eur Urol 52 (2007), 1601-1609.
11. E.F. Petricoin, C. Belluco, R.P. Araujo and LA. Liotta, The blood peptidome: A higher dimension of information content for cancer biomarker discovery, Nat Rev Cancer 6 (2006), 961-967.
12. S.M. Okarvi, Peptide-based radiopharmaceutical and cytotoxic conjugates: Potential tools against cancer, Cancer Treat Rev 34 (2008), 13-26.
13. GL. Perkins, ED. Slater and GK. Sanders, SerumTumor Markers, Am Fam Physician 68 (2003), 1075-1082.
14. S.F. Shariat, J.A. Karam, V. Margulis and P.I. Karakiewicz, New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer, BJU Int 101 (2008), 675-683.
15. J.A. Ludwig and J.N. Weinstein, Biomarkers in Cancer Staging, Prognosis and Treatment Selection, Nat Rev Cancer 5 (2005), 845-856.
16. T.C. Poon, T.S. Mok, A.T. Chan, C.M. Chan, V. Leong, S.H. Tsui, T.W. Leung, H.T. Wong, S.K. Ho and P.J. Johnson, Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein, Clin Chem 48 (2002), 1021-1027.
17. K.S. Goonetilleke and A.K. Siriwardena, Systematic review of carbohydrate antigen (CA19.9) as a biochemical marker in the diagnosis of pancreatic cancer, EJSO 33 (2007), 266-270.
18. R. Peracaula, G. Tabares, L.Royle, D.J. Harvey, R.A Dwek, P.M Rudd and R. de Llorens, Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins, Glycobiology 13 (2003), 457-470.
19. G. Tabares, C.M. Radcliffe, S. Barrabes, M. Ramirez, R.N. Aleixandre, W. Hoesel, R.A. Dwek, P.M. Rudd, R. Peracaula and R. de Llorens, Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA, Glycobiology 16 (2006), 132-145.
20. G. Tabares, K. Jung, J. Reiche, C. Stephan, M. Lein, R. Peracaula, R. de Llorens and W. Hoesel, Free PSA forms in prostatic tissue and sera of prostate cancer patients: Analysis by 2-DE and western blotting of immunopurified samples, Clin Biochem 40 (2007), 343-350.
21. R. Peracaula, L. Royle, G. Tabares, G. Mallorqui-Fernández, S. Barrabés, D.J. Harvey, R.A. Dwek, P.M. Rudd, and R.de Llorens, Glycosylation of human pancreatic ribonuclease: Differences between normal and tumor states, Glycobiology 13 (2003), 227-244.
22. S. Barrabés, L.Pagès-Pons, C.Radcliffe, G. Tabares, E. Fort, L. Royle, D. Harvey; M. Moenner, R.A Dwek, P.M.Rudd, R. de Llorens and R. Peracaula, Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer, Glycobiology 17 (2007), 388-400.
23. R. Saldova, L. Royle, C.M. Radcliffe, U.M. Abd Hamid, R. Evans, J.N. Arnold, R.E. Banks, R. Hutson, D.J. Harvey, R. Antrobus, S.M. Petrescu, R.A. Dwek and P.M. Rudd, Ovarian Cancer is Associated with Changes in Glycosylation in Both Acute-Phase Proteins and IgG, Glycobiology 17 (2007), 1344-1356.
24. G. Durand and N. Seta, Protein glycosylation and diseases: Blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring, Clin Chem 46 (2000), 795-805.
25. P.M. Rudd and R.A. Dwek, Structural Glycobiology in Medicine. Carbohydrates and Glycoconjugates, Curr Opinion in Struct Biol 16 (2006), 559-560.
26. R. Peracaula, Altered glycosylation in tumour proteins: Biological implications, Afinidad 64 (2007), 346-355.
27. D.H. Dube and C.R. Bertozzi, Glycans in cancer and inflammation-potential for therapeutics and diagnostics, Nat Rev Drug Discov 4 (2005), 477-488.
28. M. Aubert, L. Panicot, C. Crotte, P. Gibier, D. Lombardo, MO. Sadoulet and E. Mas, Restoration of α (1, 2)fucosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells, Cancer Res 60 (2000), 1449-1456.
29. M. Aubert, L. Panicot-Dubois, C. Crotte, V. Sbarra, D. Lombardo, MO. Sadoulet and E. Mas, Peritoneal colonization by human pancreatic cells is inhibited by antisense FUT3 sequence, Int J Cancer 88 (2000), 558-565.
30. M.M. Fuster and J.D. Esko, The sweet and sour of cancer: Glycans as novel therapeutic targets, Nat Rev Cancer 5 (2005), 526-542.
31. R. Kannagi, Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. Glycoconj J 20 (2004), 353-364.
32. J.L. Magnani, The discovery, biology, and drug development of sialyl Lea and sialyl Lex, Arch Biochem Biophys 426 (2004), 122-131.
33. P. Nangia-Makker, J. Conklin, V. Hogan and A. Raz, Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents, Trends Mol Med 8 (2002), 187-192.
34. E.A. Partridge, C. Le Roy, G.M. Di Guglielmo, J. Pawling, P. Cheung, M. Granovsky, I.R. Nabi, J.L. Wrana and J.W. Dennis, Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis, Science 306 (2004), 120-124.
35. H.B. Guo, M. Randolph and M. Pierce, Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: Inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase, J Biol Chem 282 (2007), 22150-22162.
36. K. Ohtsubo and J.D. Marth, Glycosylation in cellular mechanisms of health and disease, Cell 126 (2006), 855-867.
37. R. Peracaula, G. Tabarés, A. López-Ferrer, R. Brossmer, C. de Bolós, and R. de Llorens, Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreàtic tumour cells, Glycoconj J 22 (2005), 135-144.
38. J. Renkonen, O. Tynninen, P. Hayry, T. Paavonen and R. Renkonen, Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites, Am J Pathol 161 (2002), 543-550.
39. B. Buckminster Farrow and M. Evers, Inflammation and the development of pancreatic cancer, Surgical Oncology 10 (2002), 153-169.
40. K. Higai, N. Miyakazi, Y. Azuma and K.Matsumoto, Interleukin-1β induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene, FEBS Letters 580 (2006), 6069-6075.
41. A.M. Ward, J.W Catto and F.C. Hamdy, Prostate specific antigen: Biology, biochemistry and available commercial assays, Ann Clin Biochem 38 (2001), 633-651.
42. S.P.Balk, Y.J. Ko and G.J. Bubley, Biology of prostate-specific antigen, J Clin Oncol 21 (2003), 383-391.
43. S. Bracarda, O. de Cobelli, C. Greco, T. Prayer-Galetti, R. Valdagni, G. Gatta, F. de Braud, and G. Bartsch, Cancer of the prostate, Crit Rev Oncol Hematol 56 (2005), 379-396.
44. S.D. Mikolajczyk, L.S. Marks, A.W. Partin and H.G. Rittenhouse, Free prostate-specific antigen in serum is becoming more complex, Urology 59 (2002), 797-802.
45. W.J. Catalona, D.S. Smith, T.L. Ratliff, K.M. Dodds, D.E. Coplen, J.J. Yuan, J.A. Petros, and G.L. Andriole, Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991), 1156-1161.
46. I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L Parnes, L.M Minasian, L.G. Ford, S.M. Lippman, E.D. Crawford, J.J Crowley and C.A. Jr. Coltman, Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millilitre, N Engl J Med 350 (2004), 2239-2246.
47. M.K. Brawer, G.E. Meyer, J.L. Letran, D.D. Bankson, D.L. Morris, K.K. Yeung and W.J. Allard, Measurement of complexed PSA improves specificity for early detection of prostate cancer, Urology 52 (1998), 372-378.
48. W.J. Catalona, P.C. Southwick, K.M. Slawin, A.W.Partin, M.K. Brawer, R.C. Flanigan, A. Patel, J.P. Richie, P.C. Walsh, P.T. Scardino, P.H. Lange, G.H. Gasior, K.G. Loveland and K.R. Bray, Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, Urology 56 (2000), 255-260.
49. S.D. Mikolajczyk, W.J. Catalona, C.L. Evans, H.J. Linton, L.S. Millar, K.M. Marker, D. Katir, A. Amirkhan and H.G. Rittenhouse, Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer, Clin Chem 50 (2004), 1017-1025.
50. H.J. Linton, L.S. Marks, L.S. Millar, C.L. Knott, H.G Ritten-house and S.D. Mikolajczyk, Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem 49 (2003), 253-259.
51. T. Okada, Y.Sato, N. Kobayashi, K. Sumida, S. Satomura, S. Matsuura, M. Takasaki and T. Endo, Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid, Biochim Biophys Acta 1525 (2001), 149-160.
52. P.S. Basu, R. Majhi and S.K. Batabyal, Lectin and serum-PSA interaction as a screening test for prostate cancer, Clin Biochem 36 (2003), 373-376.
53. C. Ohyama, M. Hosono, K. Nitta, M. Oh-eda, K. Yoshikawa, T. Habuchi, Y. Arai and M. Fukuda, Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy, Glycobiology 14 (2004), 671-679.
54. J.P. Charrier, C. Tournel, S. Michel, P. Dalbon, and M. Jolivet, Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia, Electrophoresis 20 (1999), 1075-1081.
55. T. Isono, T. Tanaka, S. Kageyama, and T. Yoshiki, Structural diversity of cancer-related and non-cancer-related prostate-specific antigen, Clin Chem 48 (2002), 2187-2194.
56. K. Jung, J. Reiche, A. Boehme, C. Stephan, S.A. Loening, D. Schnorr, W. Hoesel, and P. Sinha, Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: Potential to improve diagnosis of prostate cancer, Clin Chem 50 (2004), 2292-2301.
57. J. Peter, C. Unverzagt and W. Hoesel, Analysis of free prostate-specific antigen (PSA) after chemical release fromthe complex with alpha(1)- antichymotrypsin (PSA-ACT), Clin Chem 46 (2000), 474-482.
58. A. Sarrats, Analysis of the Serum Prostate Specific Antigen (PSA) forms to Improve the Prostate Cancer Diagnosis, Master Thesis, University of Girona, 2007.
59. J. Weickmann and D. Glitz, Human ribonucleases: Quantitation of pancreatic-like enzimes in serum, urine and organ preparation, J Biol Chem 257 (1982), 8705-8710.
60. J. Futami, Y. Tsushima, Y. Murato, H. Tada, J. Sasaki, M. Seno and H. Yamada, Tissue-specific expression of pancreatic-type Rnases and Rnase inhibitors in humans, DNA Cell Biol 16 (1997), 413-419.
61. E. Fernández-Salas, R. Peracaula, M. Frazier and R. de Llorens, Ribonucleases expressed by human pancreatic adenocarcinoma cell lines, Eur J Biochem 267 (2000), 1484-1494.
62. K. Reddi and J. Holland, Elevated serum ribonuclease in patients with pancreatic cancer, Proc Natl Acad Sci 73 (1976), 2308-2310.
63. D. Maor and M.J. Mardiney, Alteration of human serum ribonuclease activity in malignancy, CRC. Crit Rev Clin Lab Sci 10 (1978), 89-111.
64. J. Weickmann, E. Olson and D. Glitz, Immunological assay of pancreatic ribonuclease in serum as an indicator of pancreatic cancer, Cancer Res 44 (1984), 1682-1687.
65. M. Kurihara, M. Ogawa, T. Ohta, E. Kurokawa, T. Kitahara, K. Matsuda, G. Kosaki, T. Watanabe and H. Wada, Radioimmunoassay for human pancreatic ribonuclease and measurement of serum immunoreative pancreatic ribonuclease in patients with malignant tumors, Cancer Res 44 (1984), 2240-2243.
66. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet and P. Boyle, Estimates of the cancer incidence and mortality in Europe in 2006, Ann Oncol 18 (2007), 581-592.
67. T. Grote and C. Logsdon, Progress on molecular markers of pancreatic cancer, Curr Opin Gastroenterol 23 (2007), 508-518.
68. J. Landré, P. Hewett, J. Olivot, P. Friedl, Y. Ko, A. Sachinidis and M. Moenner, Human endothelial cells selectively express large amounts of pancreatic-type ribonuclease (RNase 1), J Cell Biochem 86 (2002), 540-552.
69. B.J. Campbell, L-G. Yu and J. M. Rhodes, Altered glycosylation in inflammatory bowel disease: A possible role in cancer development, Glycoconj J 18 (2001), 851-858.
70. K. Moriwaki, K Noda, T. Nakagawa, M. Asahi, H. Yoshihara, N. Taniguchi, N. Hayashi and E. Miyoshi, A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation, Glycobiology 17 (2007), 1311-1320.
71. N. Okuyama, Y. Ide, M. Nakano, T. Nakagawa, K. Yamanaka, K. Moriwaki, K. Murata, H. Ohigashi, S. Yokoyama, H. Eguchi, O. Ishikawa, T. Ito, M. Kato, A. Kasahara, S. Kawano, J. Gu, N. Taniguchi and E. Miyoshi, Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation, Int J Cancer 118 (2006), 2803-2808.